解码上海生物医药全链条创新生态——走进上海生物医药创新成果展

Core Insights - The Shanghai Biopharmaceutical Innovation Achievements Exhibition showcases the progress made during the "14th Five-Year Plan" period, emphasizing innovation-driven development and reform in the biopharmaceutical sector [1][2]. Group 1: Innovation and Achievements - Shanghai has approved a total of 30 domestic Class 1 innovative drugs and 45 domestic Class 3 innovative medical devices from 2021 to September 2025, demonstrating its leading position in drug and device innovation in China [2]. - The number of overseas licensing transactions (License-out) from Shanghai reached 38 in 2024, accounting for 35% of the national total, with transaction amounts reaching $30.7 billion, representing 47% of the national total [2]. - Shanghai's research output in top-tier journals has increased significantly, with 3 out of 12 papers in the "Best of Cell 2024" list published by Shanghai researchers, and a total of 127 papers published in four major medical journals from 2021 to 2024 [3]. Group 2: Policy and Reform - The exhibition highlights 14 policy regulations and special measures introduced during the "14th Five-Year Plan" to promote high-quality development in the biopharmaceutical sector, covering areas such as drug regulation, medical device innovation, and clinical trials [5]. - New policies, including the "Opinions on Supporting the Full-Chain Innovation Development of the Biopharmaceutical Industry," aim to enhance the policy framework and support for the biopharmaceutical sector [5]. Group 3: Industry Growth and Structure - The biopharmaceutical industry in Shanghai has grown from ¥761.71 billion in 2021 to ¥984.70 billion in 2024, with a compound annual growth rate of 8.94%, and is expected to exceed ¥1 trillion in 2025 [6]. - By the end of 2024, Shanghai had 2,183 biopharmaceutical enterprises, including 675 manufacturing, 569 service, and 939 wholesale enterprises, indicating a robust industry structure [6]. - Major multinational pharmaceutical companies have established headquarters or R&D centers in Shanghai, with 19 out of the top 20 global pharmaceutical and medical device companies present [6]. Group 4: Financial Support and Investment - Shanghai's biopharmaceutical companies have been active in IPOs, with 102 companies listed across A-shares, Hong Kong, and the US, and several more in the pipeline [7]. - The Shanghai State Investment Corporation established a biopharmaceutical industry mother fund with a total scale of ¥22.5 billion to support the development of the biopharmaceutical innovation ecosystem [7].